3 Results for "

BDL model

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "BDL model" in MCE Product Catalog:

Cat. No.: HY-161506
CAS No.: 3027833-49-1
Research Areas:  

Inflammation/Immunology

PDE1-IN-7 (Compound 13h) is a selective inhibitor of bPDE1 (IC50= 10 nM). PDE1-IN-7 exhibits significant anti-fibrotic effects in a BDL-induced liver fibrosis rat model. PDE1-IN-7 can be used for research in liver fibrosis .
loading...
    loading...
Cat. No.: HY-150787
CAS No.: 2477873-64-4
Target:  

FXR Cytochrome P450

Research Areas:  

Metabolic Disease

BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. BMS-986339 can be used in the research of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), anti-fibrosis .
loading...
    loading...
Cat. No.: HY-181655
CAS No.: 3127060-85-6
Target:  

Cathepsin

Research Areas:  

Metabolic Disease

Anti-hepatic fibrosis agent 3 is an orally active anti-hepatic fibrosis compound targeting Cathepsin D. Anti-hepatic fibrosis agent 3 shows an IC50 of 53.18 μM against COL1A1-promoter and a Kd of 8.86 μM for binding to Cathepsin D. Anti-hepatic fibrosis agent 3 directly binds to and promotes the degradation of Cathepsin D, with no significant effect on Cathepsin B or Cathepsin L. Anti-hepatic fibrosis agent 3 inhibits hepatic stellate cell activation and reduces extracellular matrix deposition and inflammatory cytokine expression. Anti-hepatic fibrosis agent 3 exhibits remarkable anti-fibrotic activity in rat BDL and mouse CDAHFD-induced hepatic fibrosis models. Anti-hepatic fibrosis agent 3 can be used for the study of hepatic fibrosis .
loading...
    loading...